Santen Pharmaceutical Co., Ltd. (SZD)

Overview

Santen Pharmaceutical Co., Ltd. is a Japanese company with a global presence, focusing on the research and development, manufacture, and marketing of pharmaceuticals and medical devices. With a rich history dating back to 1890, Santen has established itself as a pioneer in the field, particularly in the area of ophthalmology. The company's mission is to improve the quality of life for patients worldwide by delivering innovative medical solutions for the treatment of various eye conditions, including glaucoma, ocular hypertension, dry eye, and more. Headquartered in Osaka, Japan, Santen continues to expand its reach and impact on the international healthcare market.

Products and Services

• Tafluprost/Timolol Maleate: A combination of a prostaglandin F2a derivative and a beta-adrenergic receptor blocker used for treating glaucoma and ocular hypertension.
• Netarsudil Mesilate and Latanoprost: A prostaglandin F2a derivative in marketing approval phase intended for the treatment of glaucoma and ocular hypertension.
• Sepetaprost: An advanced prostaglandin analogue eye drop, currently in phase 3 clinical trials, aimed at treating ocular hypertension and glaucoma.
• Latanoprost Ophthalmic Emulsion: Another prostaglandin F2a derivative filed for marketing approval specifically designed to treat glaucoma and ocular hypertension.
• Cyclosporin Ophthalmic Emulsion: Designed for the treatment of vernal keratoconjunctivitis, leveraging the immunosuppressive properties of cyclosporin.
• Diquafosol Sodium: A topical treatment for dry eye that works by stimulating tear production.
• Olodaterol Hydrochloride: A beta2 receptor agonist in early-stage development (phase 1/2a) for treating dry eye.
• Sirolimus Ophthalmic Suspension: Currently in phase 2a studies for treating Fuchs endothelial corneal dystrophy and meibomian gland dysfunction.
• Epinastine Hydrochloride: An antihistamine for allergic conjunctivitis, now filed for marketing approval.
• Atropine Sulfate: A non-selective muscarinic antagonist undergoing phase 2/3 clinical trials for myopia treatment.
• AFDX0250BS: A selective muscarinic M2 antagonist in phase 2a of clinical trials, being developed for myopia management.
• Ursodeoxycholic Acid: In phase 2a clinical trials for the treatment of presbyopia, showcasing the company's innovation in addressing age-related vision loss.
• Oxymetazoline Hydrochloride: A direct-acting alpha adrenergic receptor agonist in phase 3 for the treatment of ptosis, illustrating Santen's commitment to addressing a broad range of eye health issues.